Stemline Therapeutics is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics.
The goal of our dedicated team of scientists, specialists, researchers, and developers is to build a leading biopharmaceutical company focused on improving the lives of cancer patients by developing and commercializing novel first-in-class therapeutics.
In December 2018, the US Food and Drug Administration (FDA) approved ELZONRIS, a targeted therapy directed to CD123, for the treatment of adult and pediatric patients, 2 years or older, with blastic plasmacytoid dendritic cell neoplasm (BPDCN). In January 2019, a marketing authorization application (MAA) for ELZONRIS for the treatment of patients with BPDCN, was submitted to the EMA. Previously, the EMA granted accelerated assessment status to the MAA. ELZONRIS is also being evaluated in clinical trials in additional indications including chronic myelomonocytic leukemia (CMML), myelofibrosis (MF) and others. Additional Stemline clinical candidates include SL-801 and SL-701. SL-801, a novel oral small molecule reversible inhibitor of XPO1, is currently in a Phase 1 trial of patients with advanced solid tumors. SL-701, an immunotherapeutic, has completed a Phase 2 trial in patients with second-line glioblastoma.
Stemline was founded in 2003 and is headquartered in New York City.
To build a leading commercial stage biopharmaceutical company focused on improving the lives of cancer patients by developing and marketing innovative oncology therapeutics that target difficult-to-treat cancers